PE20190356A1 - Receptores quimericos y metodos de uso de los mismos - Google Patents
Receptores quimericos y metodos de uso de los mismosInfo
- Publication number
- PE20190356A1 PE20190356A1 PE2018001934A PE2018001934A PE20190356A1 PE 20190356 A1 PE20190356 A1 PE 20190356A1 PE 2018001934 A PE2018001934 A PE 2018001934A PE 2018001934 A PE2018001934 A PE 2018001934A PE 20190356 A1 PE20190356 A1 PE 20190356A1
- Authority
- PE
- Peru
- Prior art keywords
- seqs
- amino acid
- acid sequence
- group
- sequence selected
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 abstract 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 abstract 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
Abstract
Se refiere a receptores de antigenos quimericos que comprende una molecula de union antigeno que se une especificamente a la lecitina tipo C-1 (CLL-1), en donde la molecula de union a antigeno comprende al menos uno de: a) una CDR1 de cadena pesada variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 17, 51, 73 y 95; b) una CDR2 de cadena pesada variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 18, 52, 74 y 96; c) una CDR3 de cadena pesada variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 19, 53, 75 y 975; d) una CDR1 de cadena ligera variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 22, 56, 78 y 100; e) una CDR2 de cadena ligera variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 23, 57, 79 y 101; f) una CDR3 de cadena ligera variable que comprende una secuencia de aminoacidos seleccionada del grupo que consiste en las SEC. ID. NO: 24, 58, 80 y 102. Tambien comprende al menos un dominio coestimulador y un dominio de activacion. Tambien se refiere a un metodo de tratamiento contra la leucemia, linfoma o mieloma, artritis reumatoide, psoriasis, asma, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317068P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190356A1 true PE20190356A1 (es) | 2019-03-07 |
Family
ID=59960746
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001934A PE20190356A1 (es) | 2016-04-01 | 2017-03-31 | Receptores quimericos y metodos de uso de los mismos |
| PE2020001605A PE20211418A1 (es) | 2016-04-01 | 2017-03-31 | Receptores quimericos y metodos de uso de los mismos |
| PE2019002307A PE20200400A1 (es) | 2016-04-01 | 2017-03-31 | Receptores quimericos y metodos de uso de los mismos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001605A PE20211418A1 (es) | 2016-04-01 | 2017-03-31 | Receptores quimericos y metodos de uso de los mismos |
| PE2019002307A PE20200400A1 (es) | 2016-04-01 | 2017-03-31 | Receptores quimericos y metodos de uso de los mismos |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10597456B2 (es) |
| EP (2) | EP4180449A1 (es) |
| JP (5) | JP2019513370A (es) |
| KR (7) | KR20210089262A (es) |
| CN (2) | CN113150170B (es) |
| AR (1) | AR108066A1 (es) |
| AU (3) | AU2017240788B2 (es) |
| BR (1) | BR112018070260A2 (es) |
| CA (2) | CA3019650C (es) |
| CL (5) | CL2018002797A1 (es) |
| CO (1) | CO2018010547A2 (es) |
| CR (2) | CR20180480A (es) |
| DK (1) | DK3436030T3 (es) |
| EA (1) | EA201891992A1 (es) |
| ES (1) | ES2930058T3 (es) |
| HR (1) | HRP20221348T1 (es) |
| HU (1) | HUE060645T2 (es) |
| IL (2) | IL262041B2 (es) |
| LT (1) | LT3436030T (es) |
| MA (1) | MA43603A1 (es) |
| MX (2) | MX2018012019A (es) |
| MY (1) | MY197669A (es) |
| PE (3) | PE20190356A1 (es) |
| PH (1) | PH12018502113A1 (es) |
| PL (1) | PL3436030T3 (es) |
| PT (1) | PT3436030T (es) |
| RS (1) | RS63735B1 (es) |
| SG (2) | SG10201912519VA (es) |
| SI (1) | SI3436030T1 (es) |
| SM (1) | SMT202200444T1 (es) |
| TW (5) | TW201803896A (es) |
| UA (2) | UA123276C2 (es) |
| WO (1) | WO2017173384A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| HUE054936T2 (hu) | 2016-03-31 | 2021-10-28 | Janssen Pharmaceuticals Inc | Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai |
| CA3013407A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| SG11201808411RA (en) * | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| CN117903307A (zh) | 2016-04-01 | 2024-04-19 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR20210089262A (ko) | 2016-04-01 | 2021-07-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| EP3436004B1 (en) | 2016-04-01 | 2024-12-11 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EA201992782A1 (ru) | 2017-05-22 | 2020-03-24 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
| EA039702B1 (ru) | 2017-05-22 | 2022-03-01 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
| EP3710471A1 (en) | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| KR20210046006A (ko) * | 2018-08-10 | 2021-04-27 | 상가모 테라퓨틱스 프랑스 | Tnfr2 도메인을 포함하는 신규한 car 작제물 |
| JP2022505921A (ja) * | 2018-10-26 | 2022-01-14 | カファ セラピューティクス リミテッド | Ｃｌｌ１を標的とする抗体およびその応用 |
| SG11202108011UA (en) | 2019-03-01 | 2021-08-30 | Allogene Therapeutics Inc | Dll3 targeting chimeric antigen receptors and binding agents |
| CN114026118A (zh) * | 2019-05-07 | 2022-02-08 | 里兰斯坦福初级大学理事会 | 通过铰链结构域增强多肽和嵌合抗原受体 |
| WO2021003432A1 (en) | 2019-07-02 | 2021-01-07 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| BR112022004594A2 (pt) * | 2019-09-13 | 2022-08-02 | Memorial Sloan Kettering Cancer Center | Receptor de reconhecimento de antígeno, célula, molécula de ácido nucleico, vetor, célula hospedeira, composição, métodos e kit |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN113980134B (zh) | 2020-12-11 | 2022-05-31 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| CN113416713A (zh) * | 2021-05-11 | 2021-09-21 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种重组腺病毒的构建及其应用 |
| CN115521917A (zh) * | 2021-06-25 | 2022-12-27 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| US20250101104A1 (en) | 2022-01-26 | 2025-03-27 | Mabswitch Inc. | Bispecific molecule with tunable affinity to a targeted antigen |
| TW202340457A (zh) * | 2022-02-28 | 2023-10-16 | 美商凱特製藥公司 | 同種異體治療細胞 |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
| GB202301949D0 (en) | 2023-02-10 | 2023-03-29 | Coding Bio Ltd | CLL1 and/or CD33 binding molecules |
| WO2024186695A2 (en) * | 2023-03-03 | 2024-09-12 | Trustees Of Boston University | Immune cell fusion (icf) and uses thereof |
| AU2024257525A1 (en) * | 2023-04-18 | 2025-11-20 | Board Of Regents, The University Of Texas System | Bcma chimeric antigen receptors and uses thereof |
| WO2025194098A1 (en) | 2024-03-14 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Engineered immune cells expressing chimeric antigen receptors targeting trop2, and methods of using the same |
| WO2025231376A1 (en) * | 2024-05-03 | 2025-11-06 | Kite Pharma, Inc. | Chimeric receptors binding to cll-1 and methods of use thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| EP1257632B1 (en) | 2000-02-24 | 2007-09-12 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| CA2526284C (en) * | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| DE112005002126B4 (de) | 2004-09-03 | 2018-05-09 | General Motors Corp. | Ausrichtungssystem und -verfahren für sich wiederholende und nicht wiederholende Einheiten in einem Brennstoffzellenstapel |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| WO2010058023A1 (en) | 2008-11-24 | 2010-05-27 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity t cell receptor and use thereof |
| NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| JP5934099B2 (ja) | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| CN102770543A (zh) | 2009-11-17 | 2012-11-07 | 巴斯夫植物科学有限公司 | 具有增加的产量的植物 |
| EP2566886A1 (en) | 2010-05-05 | 2013-03-13 | Addex Pharma SA | Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2665521A4 (en) | 2011-01-18 | 2014-09-03 | Univ Pennsylvania | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
| ES2841983T3 (es) | 2011-03-23 | 2021-07-12 | Hutchinson Fred Cancer Res | Método y composiciones para inmunoterapia celular |
| SG194176A1 (en) | 2011-05-27 | 2013-12-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| EP2756521A4 (en) | 2011-09-16 | 2015-04-22 | Univ Pennsylvania | RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER |
| DE102012204596A1 (de) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs |
| WO2013142034A1 (en) | 2012-03-23 | 2013-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| EP3520821A1 (en) | 2012-04-02 | 2019-08-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| KR102086874B1 (ko) | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| CN104968682A (zh) | 2013-02-05 | 2015-10-07 | 英格玛布股份公司 | 针对CD3ε和BCMA的双特异性抗体 |
| CA2904014C (en) | 2013-02-06 | 2021-06-15 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
| AU2014216130B2 (en) | 2013-02-15 | 2017-11-16 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
| EP2968502B1 (en) | 2013-03-14 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| AU2014265487B2 (en) | 2013-05-14 | 2020-10-22 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
| JP6543626B2 (ja) | 2013-07-29 | 2019-07-10 | ブルーバード バイオ， インコーポレイテッド | 多部分シグナル伝達タンパク質およびその使用 |
| EP3074419B1 (en) | 2013-11-25 | 2018-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| ES2989838T3 (es) | 2014-02-04 | 2024-11-27 | The United States Of America As Represented Bythe Sec Dep Of Health And Humanservices | Métodos para producir células T autólogas útiles para tratar malignidades de células B y otros cánceres y composiciones de las mismas |
| AU2015218396A1 (en) | 2014-02-14 | 2016-08-11 | Bellicum Pharmaceuticals, Inc. | Methods for activating T cells using an inducible chimeric polypeptide |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| AU2015248956B2 (en) | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| JP6736540B2 (ja) * | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
| CA2956002C (en) | 2014-07-24 | 2023-06-27 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| RU2749922C2 (ru) | 2014-09-19 | 2021-06-21 | Сити Оф Хоуп | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 |
| BR112017005245A2 (pt) | 2014-09-19 | 2017-12-12 | Regeneron Pharma | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. |
| CA2969704C (en) | 2014-12-05 | 2023-05-02 | City Of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
| JP6671370B2 (ja) | 2014-12-12 | 2020-03-25 | ブルーバード バイオ， インコーポレイテッド | Ｂｃｍａキメラ抗原受容体 |
| ES3039918T3 (en) | 2015-04-13 | 2025-10-27 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| CN117903307A (zh) | 2016-04-01 | 2024-04-19 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| UA128326C2 (uk) | 2016-04-01 | 2024-06-12 | Амджен Інк. | Химерний рецептор до flt3 та спосіб його застосування |
| KR20210089262A (ko) | 2016-04-01 | 2021-07-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
-
2017
- 2017-03-31 KR KR1020217021089A patent/KR20210089262A/ko not_active Ceased
- 2017-03-31 KR KR1020187031572A patent/KR102120815B1/ko active Active
- 2017-03-31 UA UAA201809953A patent/UA123276C2/uk unknown
- 2017-03-31 EP EP22191077.1A patent/EP4180449A1/en active Pending
- 2017-03-31 PT PT177768595T patent/PT3436030T/pt unknown
- 2017-03-31 IL IL262041A patent/IL262041B2/en unknown
- 2017-03-31 CN CN202110248927.7A patent/CN113150170B/zh active Active
- 2017-03-31 SG SG10201912519VA patent/SG10201912519VA/en unknown
- 2017-03-31 HU HUE17776859A patent/HUE060645T2/hu unknown
- 2017-03-31 SG SG11201808595WA patent/SG11201808595WA/en unknown
- 2017-03-31 CA CA3019650A patent/CA3019650C/en active Active
- 2017-03-31 AU AU2017240788A patent/AU2017240788B2/en active Active
- 2017-03-31 PE PE2018001934A patent/PE20190356A1/es unknown
- 2017-03-31 MY MYPI2018703599A patent/MY197669A/en unknown
- 2017-03-31 EP EP17776859.5A patent/EP3436030B1/en active Active
- 2017-03-31 PE PE2020001605A patent/PE20211418A1/es unknown
- 2017-03-31 CA CA3177398A patent/CA3177398A1/en active Pending
- 2017-03-31 EA EA201891992A patent/EA201891992A1/ru unknown
- 2017-03-31 KR KR1020207015941A patent/KR20200068750A/ko not_active Ceased
- 2017-03-31 KR KR1020257007542A patent/KR20250039495A/ko active Pending
- 2017-03-31 SM SM20220444T patent/SMT202200444T1/it unknown
- 2017-03-31 PL PL17776859.5T patent/PL3436030T3/pl unknown
- 2017-03-31 AR ARP170100821A patent/AR108066A1/es unknown
- 2017-03-31 UA UAA201909739A patent/UA128781C2/uk unknown
- 2017-03-31 CR CR20180480A patent/CR20180480A/es unknown
- 2017-03-31 IL IL316403A patent/IL316403A/en unknown
- 2017-03-31 CR CR20210084A patent/CR20210084A/es unknown
- 2017-03-31 PE PE2019002307A patent/PE20200400A1/es unknown
- 2017-03-31 WO PCT/US2017/025573 patent/WO2017173384A1/en not_active Ceased
- 2017-03-31 SI SI201731265T patent/SI3436030T1/sl unknown
- 2017-03-31 KR KR1020237040899A patent/KR102731644B1/ko active Active
- 2017-03-31 US US15/476,699 patent/US10597456B2/en active Active
- 2017-03-31 HR HRP20221348TT patent/HRP20221348T1/hr unknown
- 2017-03-31 BR BR112018070260A patent/BR112018070260A2/pt active Search and Examination
- 2017-03-31 JP JP2018551953A patent/JP2019513370A/ja active Pending
- 2017-03-31 DK DK17776859.5T patent/DK3436030T3/da active
- 2017-03-31 MX MX2018012019A patent/MX2018012019A/es unknown
- 2017-03-31 KR KR1020247037911A patent/KR102779944B1/ko active Active
- 2017-03-31 ES ES17776859T patent/ES2930058T3/es active Active
- 2017-03-31 LT LTEPPCT/US2017/025573T patent/LT3436030T/lt unknown
- 2017-03-31 RS RS20221024A patent/RS63735B1/sr unknown
- 2017-03-31 MA MA43603A patent/MA43603A1/fr unknown
- 2017-03-31 KR KR1020227039755A patent/KR102608405B1/ko active Active
- 2017-03-31 CN CN201780022074.7A patent/CN109641008B/zh active Active
- 2017-04-05 TW TW106111224A patent/TW201803896A/zh unknown
- 2017-04-05 TW TW113133719A patent/TW202503052A/zh unknown
- 2017-04-05 TW TW109145084A patent/TWI792123B/zh active
- 2017-04-05 TW TW109107507A patent/TWI714470B/zh active
- 2017-04-05 TW TW112101087A patent/TWI855499B/zh active
-
2018
- 2018-10-01 CL CL2018002797A patent/CL2018002797A1/es unknown
- 2018-10-01 MX MX2023002556A patent/MX2023002556A/es unknown
- 2018-10-01 CO CONC2018/0010547A patent/CO2018010547A2/es unknown
- 2018-10-01 PH PH12018502113A patent/PH12018502113A1/en unknown
-
2019
- 2019-08-14 CL CL2019002310A patent/CL2019002310A1/es unknown
- 2019-10-21 US US16/658,480 patent/US20200115457A1/en not_active Abandoned
-
2020
- 2020-06-15 AU AU2020203990A patent/AU2020203990A1/en not_active Abandoned
- 2020-09-11 JP JP2020152515A patent/JP7134204B2/ja active Active
- 2020-10-15 CL CL2020002677A patent/CL2020002677A1/es unknown
-
2021
- 2021-06-30 CL CL2021001750A patent/CL2021001750A1/es unknown
-
2022
- 2022-07-08 CL CL2022001873A patent/CL2022001873A1/es unknown
- 2022-08-30 JP JP2022136417A patent/JP7451627B2/ja active Active
-
2023
- 2023-03-03 US US18/178,086 patent/US20230331855A1/en active Pending
- 2023-07-24 AU AU2023208077A patent/AU2023208077A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033511A patent/JP7673272B2/ja active Active
-
2025
- 2025-04-23 JP JP2025071243A patent/JP2025111619A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| CY1125347T1 (el) | Ειδικοι σε κλαουδινη-18.2 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων | |
| PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
| PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| MX2018000347A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
| CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| MX390920B (es) | Moléculas de unión a lag-3 y métodos de uso de las mismas. | |
| PE20180481A1 (es) | Anticuerpos de union a tau | |
| EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| MX2018003410A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| CL2017000912A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| AR105938A1 (es) | Anticuerpo anti-epha4 | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal |